CCRM Nordic, a leading organization dedicated to advancing research, development and commercialization of advanced therapy medicinal products (ATMPs), announced it has entered into an Industrial Partnership Agreement with Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics. 

By combining Bio-Rad’s expertise in digital PCR and assay development with CCRM Nordic’s know-how and lab infrastructure, the partnership aims to accelerate the translation and commercialization of ATMPs across the Nordics and Europe. The collaboration utilizes and extends CCRM Nordic’s collaborative model and ultimately enables patients to benefit sooner from transformative new treatments. 

“At Bio-Rad, we are proud to support the advancement of cell and gene therapies through precise analytical technologies. This collaboration with CCRM Nordic reflects our commitment to empowering researchers and developers with robust tools that accelerate innovation and uphold quality across the ATMP value chain,” said Reg Chopra, Field Marketing Director, EMEA, Bio-Rad. 

“The future of advanced therapies depends on cutting-edge science, robust analytics and reliable processes for clinical translation. By joining forces with Bio-Rad, we are equipping ATMP teams with additional digital PCR power and well-developed analytical strategies. For patients, that means new hope delivered sooner,” said Fredrik Wessberg, CEO, CCRM Nordic.  

As part of the agreement, Bio-Rad also becomes a member of CCRM Nordic’s industry consortium, a collaborative network of innovators and industry leaders including AstraZeneca, Cytiva, and others—each contributing unique strengths to accelerate the development of CCRM Nordic and ATMP development. This partnership will further enhance CCRM Nordic’s ability to provide end-to-end support, from CMC strategy and scalable GMP manufacturing processes to commercialization guidance.